GO:0051915 induction of synaptic plasticity by chemical substance: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051915 describes the process by which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require.
• Chemical inducers of synaptic plasticity include drugs of abuse, opioids, psychoactive agents, and metabolic or inflammatory mediators that alter synaptic strength.
• The term is a biological process that bridges molecular pharmacology and systems neuroscience, relevant to learning, memory, addiction, and epilepsy.
• Key molecular players include NMDA receptors, AMPA receptors, and downstream signaling kinases that convert chemical signals into durable synaptic changes.
• Dysregulation of chemically induced synaptic plasticity contributes to opioid withdrawal, epileptogenesis, and neuroinflammatory joint disease models.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of genes mediating GO:0051915 in vitro and in vivo.
Description
GO:0051915, induction of synaptic plasticity by chemical substance, is a Gene Ontology biological process term defined as the process in which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require. This term captures a fundamental interface between pharmacology and neurobiology: exogenous or endogenous chemicals can trigger lasting modifications in synaptic efficacy, including long-term potentiation (LTP) and long-term depression (LTD), which underlie learning, memory, and maladaptive states such as addiction. Unlike activity-dependent plasticity initiated by electrical stimulation, GO:0051915 specifically requires a chemical substance as the inducing agent, encompassing drugs, metabolites, and signaling molecules. Researchers study GO:0051915 to understand how chemical exposures remodel neural circuits. For example, opioid withdrawal induces synaptic LTP in specific brain regions, a process that contributes to withdrawal symptoms and relapse. Psychoactive agents such as ephenidine act as NMDA receptor antagonists with ketamine-like properties, altering synaptic plasticity and potentially producing rapid antidepressant or dissociative effects. Metabolic disturbances, such as streptozotocin-induced diabetes, change the expression of inhibitory substances in enteric neurons, illustrating how chemical insults outside the brain can also affect synaptic plasticity in the periphery. The term is also relevant to developmental epileptogenesis, where injury and chemical mediators recruit circuits and promote plasticity that lowers seizure thresholds. In arthritic joints, neurovascular plasticity occurs in response to inflammatory chemicals, showing that chemically induced synaptic remodeling is not limited to the central nervous system. Thus, GO:0051915 provides a conceptual framework for linking chemical exposure to persistent synaptic and circuit-level changes across diverse physiological and pathological contexts.
induction of synaptic plasticity by chemical substance At A Glance
| GO ID | GO:0051915 |
|---|---|
| GO term | induction of synaptic plasticity by chemical substance |
| Ontology | biological_process |
| Synonym | activation of synaptic plasticity by chemical substance; activation of synaptic plasticity by drug; induction of synaptic plasticity by drug |
| Definition | The process in which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require. |
| Major function | Chemical triggering of synaptic strengthening, weakening, or structural remodeling. |
| Related processes | Long-term potentiation, long-term depression, addiction, epileptogenesis, neuroinflammation. |
| Example inducers | Opioids, ketamine-like NMDA antagonists, inflammatory mediators, metabolic stressors. |
What Is GO:0051915?
In simple terms, GO:0051915 is the process where a chemical substance flips a switch that makes synapses change their strength or structure. More formally, it is the biological process in which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require. This includes chemical triggers such as drugs, neurotransmitters, metabolites, or toxins that lead to functional or structural modifications at synapses. The term is distinct from activity-dependent plasticity because the initiating event is chemical rather than electrical or sensory.
Why Is induction of synaptic plasticity by chemical substance Important in Cell Biology?
GO:0051915 is important because it explains how chemicals, from therapeutic drugs to drugs of abuse and endogenous metabolites, can produce lasting changes in brain and peripheral circuits. This process is central to understanding addiction, where opioid withdrawal induces synaptic LTP that drives negative reinforcement and relapse. It is also critical for neuropharmacology, as compounds like ephenidine modulate NMDA receptors and synaptic plasticity with potential antidepressant or psychotomimetic effects. In disease, chemically induced plasticity contributes to epileptogenesis after injury and to neurovascular remodeling in inflammatory arthritis. Studying this term helps researchers identify molecular targets for interventions that prevent or reverse maladaptive plasticity.
• Provides a mechanistic link between chemical exposure and persistent synaptic changes underlying learning and memory.
• Explains how drugs of abuse and withdrawal induce LTP, contributing to addiction and relapse.
• Relevant to epilepsy, where chemical mediators and injury recruit circuits and promote epileptogenesis.
• Involved in peripheral neuroplasticity, such as neurovascular changes in arthritic joints.
• Key for understanding psychoactive agents like ephenidine that target NMDA receptors and alter plasticity.
• Implicated in metabolic disorders, as diabetes changes inhibitory substance expression in enteric neurons.
• Guides development of therapeutics that modulate synaptic plasticity for psychiatric and neurological disorders.
• Offers a framework for CRISPR-based causal studies of genes mediating chemical induction of plasticity.
• Helps interpret how carbon monoxide and other heme oxygenase metabolites may influence neuronal signaling.
• Supports research on diffusion and termination of chemically induced convulsive activity in awake animals.
What Happens During induction of synaptic plasticity by chemical substance?
Chemical sensing and receptor activation
In simple terms: A chemical lands on a receptor, like a key in a lock, and starts a signal inside the neuron.
The process begins when a chemical substance binds to or modulates synaptic receptors, notably NMDA and AMPA receptors. For example, ephenidine acts as an NMDA receptor antagonist with ketamine-like properties, altering glutamatergic signaling that is essential for synaptic plasticity. Opioid withdrawal also triggers synaptic LTP through chemical changes in the synaptic environment, indicating that receptor-level events are the first step in GO:0051915. In the insula, taste learning involves chemical and sensory inputs that converge on synaptic plasticity mechanisms.
Intracellular signaling cascades
In simple terms: The signal from the receptor sets off a chain of molecular messengers inside the cell.
Following receptor activation, intracellular kinases and phosphatases are recruited to convert the chemical signal into biochemical changes. These cascades can lead to phosphorylation of ion channels and receptors, altering synaptic strength. Opioid withdrawal-induced LTP requires such signaling events to produce lasting changes in synaptic efficacy. Similarly, psychoactive agents that target NMDA receptors initiate downstream signaling that can result in either homeostatic or pathological plasticity.
Gene expression and protein synthesis
In simple terms: The cell reads its DNA and makes new proteins to lock in the change.
For durable synaptic plasticity, chemical signals often trigger changes in gene expression and new protein synthesis. This step stabilizes the plastic changes and can convert transient modifications into long-lasting ones. In developmental epileptogenesis, injury and chemical mediators recruit circuits and promote plasticity that involves transcriptional programs. Metabolic stressors such as streptozotocin-induced diabetes also alter expression of inhibitory substances in enteric neurons, showing that chemical induction can reshape neuronal phenotype.
Structural and functional remodeling
In simple terms: The synapse physically changes shape or strength to adapt.
The final stage involves structural and functional remodeling of synapses, including changes in spine morphology, receptor trafficking, and synaptic efficacy. In arthritic joints, neurovascular plasticity occurs in response to inflammatory chemicals, demonstrating that chemically induced remodeling can affect peripheral neural structures. In the brain, opioid withdrawal-induced LTP exemplifies functional remodeling that persists beyond the initial chemical trigger. Carbon monoxide, a heme oxygenase metabolite, may also influence neuronal signaling and plasticity through interactions with metalloporphyrins.
Termination and diffusion of chemical signals
In simple terms: The chemical signal fades away, but the synaptic change can remain.
The duration and spread of the chemical inducer influence the extent of plasticity. In awake rats, diffusion contributes to the termination of penicillin-induced convulsive activity, illustrating how chemical clearance affects neural excitability. This step highlights that GO:0051915 is not only about initiation but also about the spatiotemporal dynamics of the chemical substance that determine the outcome of plasticity.
Key Genes Involved in GO:0051915 induction of synaptic plasticity by chemical substance
The following genes and proteins are central to chemical induction of synaptic plasticity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRIN1 | NMDA receptor subunit; mediates glutamatergic signaling | Target for ketamine-like agents and plasticity studies |
| GRIN2A | NMDA receptor subunit; modulates receptor properties | Implicated in synaptic plasticity and neuropsychiatric disorders |
| GRIN2B | NMDA receptor subunit; regulates calcium influx | Key for LTP and drug-induced plasticity |
| GRIA1 | AMPA receptor subunit; mediates fast synaptic transmission | Trafficking changes underlie LTP |
| GRIA2 | AMPA receptor subunit; controls calcium permeability | Important for synaptic strength regulation |
| OPRM1 | Mu-opioid receptor; mediates opioid effects | Central to opioid withdrawal-induced LTP |
| OPRK1 | Kappa-opioid receptor; modulates synaptic plasticity | Relevant to stress and addiction |
| HMOX1 | Heme oxygenase 1; produces carbon monoxide | Carbon monoxide influences neuronal signaling |
| HMOX2 | Heme oxygenase 2; constitutively produces CO | May modulate synaptic plasticity via CO |
| BDNF | Neurotrophin; promotes synaptic plasticity | Widely studied in chemical induction of plasticity |
| TRKB | BDNF receptor; activates signaling cascades | Mediates BDNF effects on plasticity |
| CAMK2A | Calcium/calmodulin-dependent kinase II | Critical for LTP induction |
| PRKACA | Protein kinase A catalytic subunit | Involved in cAMP-dependent plasticity |
| CREB1 | Transcription factor; regulates gene expression | Links chemical signals to long-term plasticity |
| FOS | Immediate early gene; marker of neuronal activation | Used to map circuits activated by chemical inducers |
| ARC | Activity-regulated cytoskeleton-associated protein | Required for synaptic remodeling |
| SLC6A4 | Serotonin transporter; modulates synaptic serotonin | Target of psychoactive substances |
| GAD1 | Glutamate decarboxylase; synthesizes GABA | Altered in diabetes-induced enteric neuropathy |
How Is induction of synaptic plasticity by chemical substance Regulated?
GO:0051915 is regulated at multiple levels. Receptor availability and subunit composition determine sensitivity to chemical inducers; for example, NMDA receptor antagonism by ephenidine modulates plasticity. Opioid withdrawal triggers LTP through changes in opioid receptor signaling. Intracellular kinases such as CAMK2A and PRKACA regulate the strength and duration of plasticity. Transcription factors like CREB1 mediate gene expression changes that stabilize plasticity. Metabolic and inflammatory mediators can also regulate the process, as seen in diabetes-induced changes in enteric neurons and arthritic neurovascular plasticity. Finally, diffusion and clearance of the chemical substance influence the termination of plastic changes.
induction of synaptic plasticity by chemical substance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OPRM1 | Opioid withdrawal and addiction | Knockout mice for withdrawal-induced LTP |
| GRIN2B | Neuropsychiatric disorders and plasticity | Point-mutation knock-in mice |
| CREB1 | Epileptogenesis and memory disorders | Conditional knockout in neurons |
| HMOX1 | Neurodegeneration and CO signaling | Overexpression or knockout models |
| GAD1 | Diabetic enteric neuropathy | Streptozotocin-treated pig or mouse models |
Addiction and opioid withdrawal
Opioid withdrawal induces synaptic long-term potentiation, a form of chemically induced plasticity that contributes to withdrawal symptoms and relapse. This process is mediated by changes in synaptic efficacy in reward-related circuits. Understanding GO:0051915 in this context may inform treatments for opioid use disorder.
Epilepsy and epileptogenesis
During development, injury and chemical mediators recruit circuits and promote plasticity that lowers seizure thresholds, contributing to epileptogenesis. Chemical induction of synaptic plasticity is therefore a key mechanism in acquired epilepsy. Additionally, diffusion of convulsant chemicals affects the termination of convulsive activity, linking chemical dynamics to seizure duration.
Neuropsychiatric and psychoactive drug effects
Psychoactive agents such as ephenidine act as NMDA receptor antagonists with ketamine-like properties, inducing synaptic plasticity that may underlie rapid antidepressant or dissociative effects. Dysregulation of these pathways is implicated in schizophrenia and mood disorders. Taste learning also involves chemical induction of plasticity in the insula, relevant to feeding and reward.
Peripheral neuropathies and inflammatory disease
In arthritic joints, neurovascular plasticity occurs in response to inflammatory chemicals, suggesting that GO:0051915 operates in peripheral tissues. Diabetes induced by streptozotocin alters expression of inhibitory substances in enteric neurons, linking metabolic chemicals to enteric neuropathy. Carbon monoxide, a heme oxygenase metabolite, may also modulate neuronal signaling in disease states.
From induction of synaptic plasticity by chemical substance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OPRM1 mediate opioid withdrawal-induced LTP? | OPRM1 knockout mouse |
| How does GRIN2B point mutation affect chemical plasticity? | GRIN2B knock-in mouse with point mutation |
| Can CREB1 overexpression enhance chemically induced plasticity? | CREB1 overexpression transgenic mouse |
| What is the role of HMOX1 in CO-mediated plasticity? | HMOX1 knockout or overexpression cells |
| Does GAD1 knockdown alter enteric neuron plasticity? | GAD1 knockout pig or mouse |
| How does ephenidine affect synaptic plasticity? | NMDA receptor subunit knockout cells |
How to Study the induction of synaptic plasticity by chemical substance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents and plasticity | LTP induction by chemicals |
| Field potential recording | Population synaptic responses | Hippocampal slice plasticity |
| Two-photon imaging | Spine morphology and calcium signals | Structural plasticity |
| RNA sequencing | Gene expression changes | Chemical-induced transcriptional programs |
| Western blot | Protein levels and phosphorylation | Signaling cascade analysis |
| Immunohistochemistry | Protein localization and expression | Enteric neuron markers |
| Behavioral assays | Withdrawal, seizure, learning | In vivo chemical induction |
| Biochemical assays | Enzyme activity (e.g., HMOX) | CO production measurement |
Electrophysiology
Patch-clamp and field potential recordings measure LTP and LTD directly after chemical application. For example, opioid withdrawal-induced LTP can be quantified in brain slices. This method provides causal evidence that a chemical substance induces synaptic plasticity.
Imaging and activity mapping
Two-photon microscopy and calcium imaging visualize structural and functional synaptic changes in response to chemicals. Immediate early gene expression (e.g., FOS) can map circuits activated during taste learning and other chemical induction paradigms.
Molecular and biochemical assays
Western blotting, immunocytochemistry, and RNA sequencing assess signaling and gene expression changes. For instance, expression of inhibitory substances in enteric neurons is measured after streptozotocin treatment. Heme oxygenase activity and CO production can be assayed biochemically.
Behavioral and pharmacological studies
Animal models of addiction, epilepsy, and arthritis are used to test chemical inducers. Withdrawal behaviors and seizure thresholds are monitored after chemical exposure. Diffusion of convulsants can be studied in awake rats.
How CRISPR Can Be Used to Study GO:0051915 induction of synaptic plasticity by chemical substance
Knockout
CRISPR knockout of genes such as OPRM1 or GRIN2B can test their necessity for chemically induced synaptic plasticity. For example, OPRM1 knockout mice fail to show opioid withdrawal-induced LTP. Knockout of HMOX1 or HMOX2 can reveal roles of CO in plasticity.
Point Mutation
Point mutations in receptor subunits (e.g., GRIN2B) can mimic human variants and assess their impact on chemical induction of plasticity. Such models help dissect domain-specific functions. Point mutations in CAMK2A can test kinase activity requirements.
Knock-in
Knock-in of tagged or reporter alleles (e.g., FOS-lacZ) allows visualization of neurons activated by chemical inducers. Knock-in of human disease variants in GRIN2B can model neuropsychiatric disorders. Knock-in of CREB1 reporters can track transcriptional activation.
Overexpression
Overexpression of BDNF or CREB1 can enhance chemically induced plasticity and test sufficiency. Overexpression of HMOX1 can increase CO production and modulate synaptic signaling. These models are useful for gain-of-function studies.
How EDITGENE Supports induction of synaptic plasticity by chemical substance Research
Researchers studying induction of synaptic plasticity by chemical substance-related genes often need to determine whether a candidate gene is causally involved in chemical sensing, signaling, or structural remodeling. EDITGENE provides comprehensive CRISPR services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous testing of genes implicated in GO:0051915.
Contact EDITGENE today to design your custom CRISPR model for induction of synaptic plasticity by chemical substance research.
Frequently Asked Questions About induction of synaptic plasticity by chemical substance
What is GO:0051915?
GO:0051915 is the Gene Ontology biological process term for induction of synaptic plasticity by chemical substance, defined as the process in which a chemical substance activates synaptic plasticity, the ability of synapses to change as circumstances require.
What genes are involved in induction of synaptic plasticity by chemical substance?
Key genes include GRIN1, GRIN2A, GRIN2B, GRIA1, GRIA2, OPRM1, OPRK1, HMOX1, HMOX2, BDNF, TRKB, CAMK2A, PRKACA, CREB1, FOS, ARC, SLC6A4, and GAD1.
How does opioid withdrawal induce synaptic plasticity?
Opioid withdrawal induces synaptic long-term potentiation through changes in synaptic efficacy in reward circuits, a process mediated by opioid receptor signaling.
What is the role of NMDA receptors in chemical induction of plasticity?
NMDA receptors, composed of GRIN subunits, are central to glutamatergic signaling that underlies synaptic plasticity. Psychoactive agents like ephenidine act as NMDA receptor antagonists with ketamine-like properties.
Can CRISPR be used to study GO:0051915?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in chemical induction of synaptic plasticity.
What diseases are linked to induction of synaptic plasticity by chemical substance?
Linked diseases include addiction and opioid withdrawal, epilepsy, neuropsychiatric disorders, and peripheral neuropathies such as diabetic enteric neuropathy.
How is synaptic plasticity measured after chemical exposure?
Electrophysiology (patch-clamp, field potentials) measures LTP and LTD, while imaging and molecular assays assess structural and biochemical changes.
What is the role of carbon monoxide in synaptic plasticity?
Carbon monoxide, a heme oxygenase metabolite, may influence neuronal signaling and plasticity through interactions with metalloporphyrins.
Does diabetes affect synaptic plasticity in the gut?
Streptozotocin-induced diabetes changes the expression of inhibitory substances in enteric neurons, indicating that metabolic chemicals can alter peripheral synaptic plasticity.
How does diffusion affect chemically induced convulsive activity?
Diffusion contributes to the termination of penicillin-induced convulsive activity in awake rats, showing that chemical clearance influences the duration of neural excitability.
Conclusion
GO:0051915, induction of synaptic plasticity by chemical substance, is a vital biological process that connects chemical exposure to lasting synaptic changes. It encompasses receptor activation, intracellular signaling, gene expression, and structural remodeling, with key roles for NMDA receptors, opioid receptors, and downstream kinases. Dysregulation of this process contributes to addiction, epilepsy, neuropsychiatric disorders, and peripheral neuropathies. CRISPR-based models from EDITGENE provide powerful tools to dissect the genetic basis of chemically induced plasticity and to identify therapeutic targets.
References
- 1. Yiannakas A et al.. 2017. The Insula and Taste Learning.. Front Mol Neurosci 10:335 PMID: 29163022
- 2. Drdla R et al.. 2009. Induction of synaptic long-term potentiation after opioid withdrawal.. Science 325(5937):207-10 PMID: 19590003
- 3. Sankar R et al.. 2002. Epileptogenesis during development: injury, circuit recruitment, and plasticity.. Epilepsia 43 Suppl 5:47-53 PMID: 12121295
- 4. Buma P et al.. 2000. Neurovascular plasticity in the knee joint of an arthritic mouse model.. Anat Rec 260(1):51-61 PMID: 10967536
- 5. Kang H et al.. 2017. Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties.. Neuropharmacology 112(Pt A):144-149 PMID: 27520396
- 6. Marks GS. 1994. Heme oxygenase: the physiological role of one of its metabolites, carbon monoxide and interactions with zinc protoporphyrin, cobalt protoporphyrin and other metalloporphyrins.. Cell Mol Biol (Noisy-le-grand) 40(7):863-70 PMID: 7849553
- 7. Bulc M et al.. 2017. Changes in expression of inhibitory substances in the intramural neurons of the stomach following streptozotocin- induced diabetes in the pig.. World J Gastroenterol 23(33):6088-6099 PMID: 28970724
- 8. Horn E et al.. 1991. The contribution of diffusion to the termination of penicillin-induced convulsive activity in the awake rat.. Arch Ital Biol 129(4):273-87 PMID: 1789715
